Assembly Biosciences, Inc.: Focused on targeting hepatitis B virus (HBV) with a portfolio of potent, oral core inhibitors, that have the potential to increase cure rates for chronically infected patients. Lead candidate 731 is in Phase 2 – has demonstrated a favorable safety profile, and decreases in cccDNA population with patients expected to be withdrawn from treatment in 2020 and followed for sustained viral DNA suppression off therapy. 2158 is expected to complete Phase 1b in Q1 2020.
Based in...
US - East North Central
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Gastrointestinal, Infectious Disease
Public, USA
Market Cap
500MM - 1B
11711 North Meridian Street
Suite 310
Carmel, IN 46032
United States

Top 10 Holders of Assembly Biosciences, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Consonance Capital Management LP 12.27 3,175,535 55.38 13F 6/30/20
Ecor1 Capital LLC 12.19 3,153,797 55.00 13F 6/30/20
Jennison Associates LLC 9.10 2,353,274 41.04 13F 6/30/20
Baker Bros. Advisors LP 5.96 1,541,618 26.89 13F 6/30/20
The Vanguard Group, Inc. 5.94 1,538,944 26.84 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 5.83 1,508,089 26.30 13F 6/30/20
Rock Springs Capital Management LP 5.79 1,498,915 26.14 13F 6/30/20
Wellington Management Co. LLP 5.41 1,399,823 24.41 13F 6/30/20
BlackRock Fund Advisors 5.31 1,375,072 23.98 13F 6/30/20
Citadel LP 4.49 1,161,369 20.25 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.